BGLC
BioNexus Gene Lab Corp
$2.03
+0.03 (+1.50%)
At close · Jul 2
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon improving its operating results and maintaining adequate liquidity. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$4.91M
Shares
2,417,314
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.03
Open$2.05
Day$2.00–2.05
52W$1.07–8.98
Avg vol 30d194K
Short int99K · 4.1% float · 1.0d
Short vol0%
DataJan 2021–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Strong Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−39% below
−
Price vs 50-day avg
−6% below
◦
RSI (14)
43 · neutral
−
MACD trend
negative
−
52-week position
12% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $2 › 200d $3 — 200d above 50d
+
Institutional flow
+100% holders QoQ · +2 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
4.10% of float · ▲ +345.2% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
2 holders — near 1-yr high, broad support
Fundamentals
Strong
−
Revenue growth
−22% Y/Y
+
Gross margin
15%, expanding
+
EPS growth
+46% Y/Y
−
Free cash flow
$-1.9M
+
Balance sheet
net cash $2.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−39% below
Bearish
Price vs 50-day avg
−6% below
Bearish
RSI (14)
43 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
12% · near low
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+100% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.10% of float · ▲ +345.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
2 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 12%
52-wk high $9
vs 200-day avg -39%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BGLC
this stock
BioNexus Gene Lab Corp
|
$4.91M | -48.6% | -21.9% | — | 4.1% |
|
LIN
Linde PLC
|
$252.88B | +28.6% | +3.0% | 36.3 | 1.6% |
|
AIQUF
L Air Liquide SA /Fi
|
$130.69B | +9.5% | — | — | 0.0% |
|
SHW
Sherwin Williams Co
|
$86.92B | +9.0% | +26.4% | 33.9 | 3.7% |
|
ECL
Ecolab Inc.
|
$79.74B | +8.2% | +2.2% | 38.3 | 1.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BGLC | -0.5% | -11.0% | -48.0% | +4.1% | -48.6% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -1.9% | -9.7% | -56.0% | +4.4% | -57.8% |